MCM
OBIO icon

Massar Capital Management’s Orchestra BioMed OBIO Stock Holding History

Massar Capital Management’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,000
Closed -$42.8K – 157
2025
Q1 		$42.8K Buy
+10,000
New +$49.7K 0.05% 110

Other funds holding OBIO

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Massar Capital Management's OBIO Position: Q2 2025 in Review

Massar Capital Management sold out of Orchestra BioMed (OBIO) in Q2 2025, closing a stake of 10,000 shares — an estimated $42.8K sold.

Massar Capital Management first reported a position in OBIO in Q1 2025 and held it in 1 quarter. The position peaked at $42.8K in Q1 2025. 59 funds tracked by Wall St. Rank hold OBIO as of Q2 2025.

  • Massar Capital Management reported no remaining Orchestra BioMed position as of Q2 2025 after selling out during the quarter.
  • Massar Capital Management sold 10,000 Orchestra BioMed shares in Q2 2025, an estimated $42.8K.
  • Massar Capital Management first reported a position in Orchestra BioMed in Q1 2025 and held it in 1 quarter.
  • Massar Capital Management's Orchestra BioMed position peaked at $42.8K in Q1 2025.
  • 59 funds tracked by Wall St. Rank held Orchestra BioMed as of Q2 2025.

Based on Massar Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.